CPHA Canvax
CPHA Canvax
PDF

"In preauthorization trials of the Pfizer-BioNTech COVID-19 vaccine, adolescents aged 12–17 years reported local and systemic mild and moderate reactions. Myocarditis has been observed after vaccination with mRNA vaccines in post authorization monitoring.

Local and systemic reactions after vaccination with Pfizer-BioNTech vaccine were commonly reported by adolescents aged 12–17 years to U.S. vaccine safety monitoring systems, especially after dose 2. A small proportion of these reactions are consistent with myocarditis.

Mild local and systemic reactions are common among adolescents following Pfizer-BioNTech vaccine, and serious adverse events are rare. The Advisory Committee on Immunization Practices conducted a risk-benefit assessment and continues to recommend the Pfizer-BioNTech COVID-19 vaccine for all persons aged ≥12 years." - United States Centers for Disease Control


Download

Related Resources

Bookmark

Evidence

PDF

Category

Vaccine Safety and Development,Vaccine Safety,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Vaccine Monitoring and Surveillance,Vaccine Monitoring,Outbreaks and Pandemics,COVID-19 Vaccine Safety and Development
Vaccine Safety
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Vaccine Monitoring and Surveillance
Vaccine Monitoring
Outbreaks and Pandemics
COVID-19

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.